djjaeger82 Tuesday, 05/04/21 11:51:53 PM Re: rafunrafun post# 338561 Post # of 339023 Was thinking the same thing, perhaps a drawn out long schedule does help induce a settlement. But I'm not sure if a settlement has the same over-arching effect that we are looking for with a ruling in our favor (to dissuade other insurers from doing the same thing for example). Will this just cause more insurers to do the same thing as UNH and discontinue any type of Vascepa support (branded or generic) just to avoid lawsuits like this one in the future? Short term, this might actually hurt Amarin. Obviously any kind of settlement/agreement with a generic producer like Hikma is good, but will it scare the others and bring them to the table too? I just worry that it further clouds the US market for a long time compared to a swift and clear resolution. (Even if the long term is in our interest, the share price will likely still struggle in my opinion. If there's one thing that wall street hates....its UNCERTAINTY). Buyouts won't want to take on any uncertainty either... And I fear this course of action will cause just more and longer uncertainty.